Alleh Lindquist, Chief Executive Officer, FloraWorks Holdings Inc. Alleh Lindquist is the Chief Executive Officer of FloraWorks Holdings Inc., a leading cannabinoid therapeutics company. In his role as CEO, he is responsible for managing and directing the company toward its primary goals and objectives, strategy and market expansions. Lindquist brings years of expertise in entrepreneurial startups, raising capital, business development, product innovation, strategy, marketing and cannabinoid R&D to his role. Under Alleh’s leadership, FloraWorks closed a $2.25M Series-A financing round. The milestone marked FloraWorks’ commitment to exploring and developing new cannabinoids with the potential to address various unmet medical needs with promising discoveries in treating sleep disorders and dementia-related diseases. Floraworks also recently announced the results of the first-ever double-blind, randomized, placebo-controlled trial that analyzed the effects of its flagship product, TruCBN™ – a pure form of Cannabinol (“CBN”). Independently conducted by clinical-research company, Radicle Science, the groundbreaking research found that the group taking 50 mg of TruCBN™ showed a significant improvement in sleep compared to placebo, and most of the group experienced a clinically important improvement. Prior to joining FloraWorks, Lindquist was a founding partner and CEO of Swell Companies, the first cannabis extraction company in the state of Oregon to receive a license and owned two notable vaporizer and cannabis oil brands. In 2019 under Alleh's direction, Swell was acquired by C21 Investments, a publicly-traded cannabis company. In addition to his work in the emerging cannabis and biotech industries, Lindquist has also worked in a variety of capacities with globally recognized brands such as Nike, Polar, and Gerber Knives.